Recombinant Human Insulin-Like Growth Factor-1 Treatment: Prime Time or Timeout?  [Commentary on “Recombinant Human Insulin Like Growth Factor-1 Treatment: Ready for Prime Time” by Bright GM, Mendoza JR, Rosenfeld RG, Endocrinol Metab  Clin N Am 2009; 38:625–38] by Rosenbloom, Arlan L.
Hindawi Publishing Corporation
International Journal of Pediatric Endocrinology
Volume 2009, Article ID 429684, 6 pages
doi:10.1155/2009/429684
Commentary
RecombinantHuman Insulin-Like Growth Factor-1 Treatment:
PrimeTimeorTimeout?
[Commentary on “RecombinantHumanInsulinLikeGrowth
Factor-1Treatment:ReadyforPrimeTime”b yB rightGM ,
MendozaJR, RosenfeldRG, EndocrinolMetab
Clin N Am 2009; 38:625–38]
Arlan L. Rosenbloom
Division of Endocrinology, Department of Pediatrics, College of Medicine, University of Florida, 1701 SW 16th Avenue,
Gainesville, FL 32608, USA
Correspondence should be addressed to Arlan L. Rosenbloom, rosenal@peds.uﬂ.edu
Received 21 October 2009; Accepted 27 October 2009
Copyright © 2009 Arlan L. Rosenbloom. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The paper by Bright et al. is an eﬀort to authenticate
the recently introduced designation of “primary insulin-like
growth factor-1 deﬁciency (IGFD)” and it’s treatment with
recombinant human insulin-like growth factor-1 (rhIGF-1).
The concept of “primary IGFD” is supported by com-
parison to states of hormone deﬁciency that occur despite
adequate stimulation to the target gland, such as pri-
mary hypothyroidism and primary hypocortisolism. This
is a specious argument. These designations of primary
abnormality are not diagnoses but provisional diagnostic
categories. While primary hypothyroidism is used as a
broad categorization, diagnosis requires, at the very least,
diﬀerentiation between congenital and acquired, both of
which include a wide range of speciﬁc diagnoses which have
prognostic and therapeutic importance. Similarly, we rarely,
if ever, speak of primary hypocortisolism, because of the
very limited information or therapeutic guidance conveyed
by a categorization that encompasses various forms of
congenital adrenal hyperplasia, autoimmune and infectious
Addison disease, adrenal leukodystrophy, and congenital
adrenal unresponsiveness.
These authors, however, are suggesting that “primary
IGFD”isaviablespeciﬁcdiagnosisapplicabletoasubstantial
proportion of children with idiopathic short stature (ISS).
Were this proposal validated, the market for recombinant
insulin-like growth factor-1 (rhIGF-1) would be greatly
expanded beyond the rare conditions resulting in growth
hormone(GH)insensitivityforwhichrhIGF-1wasapproved
by the US Food and Drug Administration (FDA) [1].
I tm a k e sn om o r es e n s et or e f e rt oG Hi n s e n s i t i v i t yo r
resistance as “primary IGFD” than it would to refer to GH
deﬁciency (GHD) as “secondary IGFD” [2]. The problem
with this designation as a useful diagnostic entity is seen in
the vast diﬀerences among the conditions subsumed, from
GH receptor and IGF-1 gene mutations, and including acid
labilesubunit(ALS)mutationasoneofthemoleculardefects
listed in Box 1 as causing “primary IGFD.” Because ALS is
needed to stabilize the complex of IGF-1 and IGFBP3 in the
circulation, its absence results in extremely low circulating
IGF-1 and IGFBP3 levels. However, there is no impairment
of IGF-1 synthesis in any tissue, making the assignment of
ALS mutation as a cause of “primary IGFD” irrational. That
the ALS deﬁciency has no eﬀect on paracrine/autocrine IGF-
1synthesisoreﬀectisthelikelyexplanationforno-to-modest
eﬀect on growth in individuals with ALS deﬁciency [3, 4].
The notion of “primary IGFD” is further advanced with
a modiﬁcation of the Venn diagram that Cohen [5]h a su s e d ,
indicating partial overlap of IGFD and GHD, and of short2 International Journal of Pediatric Endocrinology
stature and GHD, with a small shaded region overlapping
IGFD and short stature. All GHD is characterized by IGFD,
however, not simply the ∼20% showing overlap. Similarly,
the overlap between short stature and GHD should be nearly
complete, excepting only recent onset GHD, or the rare
growth without GH phenomenon. The overlap between
IGFD and short stature attributed to “primary IGFD” is
hypothetical, with the exception of the small number of
provenGHresistantpatientswhohavereceivedrhIGF-1over
thepastnearly20years(∼150individualsworldwide),which
would make the area of overlap miniscule.
In discussing the possible prevalence of “primary IGFD,”
it is assumed that the prepubertal children recruited into
the sponsored clinical trials of rhIGF-1 ﬁt this designa-
tion and “may have been categorized in previous clinical
trials as having ISS, constitutional delay, or familial short
stature.” Most of these subjects are, indeed, likely to have
constitutional delay in growth and maturation (CDGM),
the most common explanation for short stature seen in the
pediatric endocrinology clinic [6] and frequently associated
with low IGF-1, especially if the IGF-1 levels are interpreted
for chronologic age rather than for the delayed bone age or
pubertal stage.
The authors go on to note that 17% of Genentech
National Corporative Growth Study (NCGS) subjects were
classiﬁed as ISS with normal GH responses and no other
known etiology. This datum has no apparent relevance for
validating “primary IGFD,” as emphasized by the statement
that it is unknown how many had low serum IGF-1 levels.
There is, however, evidence that NCGS subjects without
GHD and having low IGF-I not only responded as well to
rhGHasthosechildrenwithnormalcirculatinglevelsofIGF-
I, but that their responses correlated inversely with baseline
IGF-I concentrations [7–9]. This observation is the opposite
of what one would expect if the low IGF-I concentrations
were the result of GH insensitivity.
Another line of purported evidence for the concept of
“primary IGFD” is that 19%–25% of subjects with short
stature and normal GH levels have IGF-1 concentrations
below normal. The references fail to support this assertion
[10,11].Onereferenceistoastudyinwhich190childrenof1
monthto20yearsofagereferredforshortstatureunderwent
GH stimulation testing with arginine. Normal peak GH
levels were seen in only 46% (as would be expected in a
largely prepubertal population in the absence of sex steroid
priming [12]), of whom 24% had IGF-1 < −2SD, based
on a single IGF-1 measurement. There is no information
about age distribution of the population within this broad
agespan,norstratiﬁcationaccordingtoboneagediscrepancy
from chronologic age. The younger extreme of the age
range would have highly unreliable IGF-1 data and the
older range is likely to include many, if not most, with
CDGM. IGF-1 SDS was determined by chronological rather
than developmental age, which would be inappropriate for
those with CDGM. There are no data on response to GH
treatment, the obvious gold standard for GH resistance.
Finally, the peak GH concentrations correlated positively
with the serum concentrations of IGF-1 only for those with
peak GH less than 7.6mcg/L, accounting for only 9% of the
v a r i a t i o ni nI G F - 1[ 10]. Were GH resistance an explanation
for the low circulating IGF-1 levels, increasing GH levels
would have correlated inversely with IGF-1 concentrations.
The other study cited was an examination of the value of
IGF-1measurementinthediagnosis ofGHDandconcluded,
“Our ﬁndings cannot fully resolve the controversy regarding
the extent to which levels of IGF peptides are important to
the diagnostic workup in children with short stature” [11].
While there is recognition of the uncertainty of IGF-
1 measurement, absent is consideration of the diﬃcult-to-
counter argument that children with CDGM should have
their IGF-1 levels interpreted for developmental (bone) age
rather than chronologic age. The data regarding lower circu-
latingIGF-IconcentrationsinISSarenotonlyhighlysuspect
because of the unreliability of the assays, but the populations
studied would be expected to include a majority of CDGM
who have substantially delayed bone age. Normal values
for IGF-1 concentrations are a function of developmental
status represented by bone age or Tanner stage. If the IGF-
1 concentrations are interpreted for chronologic age [7, 10],
theywilltypicallybelowerthannormalifthereisboneageor
pubertaldelayforchronologicage.Adelayed14-year-oldboy
withaboneageof11years(atypicalpresentation)wouldnot
have a testosterone level for a typical 14-year-old boy. Similar
logic should apply to interpreting IGF-1 measurement,
whichisalsodevelopmentalleveldependent.Inthisexample,
a reading at −2SDS for chronologic age would be read
as −1SDS for developmental age [13]. Even without this
unacknowledged variable, the extensive discussion of the
problems with IGF-1 assays and their interpretation does not
suggest conﬁdence in a diagnostic criterion based on a single
IGF-1 measurement [14].
The authors further advance the notion of varying
degrees of GH insensitivity with a novel perspective on
a paper coauthored by Bright a quarter of a century ago
[15]. One would not have realized that “the concept of
an IGF-1 deﬁciency continuum gained initial attention in
the early 1980s” by reading the original paper. Nor would
one appreciate without going to the source that “Studies of
children who had marked short stature, IGF-1 deﬁciency,
and normal-to-elevated GH levels found that the heights
and IGF-1 levels of the subjects were not reduced as severely
as for children who had Laron syndrome.” refers to a case
report of only 2 patients, or that the current description
of these patients is revisionary. The range of heights in
Laron syndrome encompasses that of the 2 subjects (−4.8
& −4.0 height SDS), and the growth velocities were 3.4
and 4.3cm/year, also well within the Laron syndrome mean
range of 3.0 to 5.0cm/year, as noted in Box 1. To determine
whether “... t h eI G F - 1l e v e l sw e r en o tr e d u c e da ss e v e r e l y
as for children who had Laron syndrome,” it is necessary
to look at data from the same era, using the same units for
somatomedin activity. The basal range for the 2 patients of
0.22–0.34U/mL is precisely midrange for Laron’s patients
who had unmistakable GH receptor deﬁciency, as reported
in 1984 [16].
Bright and associates continue this singular interpreta-
tion by stating, “These subjects were also capable of limited
growth response to pituitary-derived GH, suggesting thatInternational Journal of Pediatric Endocrinology 3
they may have partial, but not complete, GH insensitivity.”
In the 1983 paper, however, one patient is reported to
have grown at a velocity of 8cm/year and the other at
12cm/year during the 6-month study period, which in 1983
they described as an excellent response. This interpretation
wascorrectinthecontextoftheera,asaresponsetopituitary
extract GH given 3 times a week instead of the contemporary
more eﬀective daily injection, and at a total dose per week
that was approximately half the current minimum starting
dose of rhGH for GHD. Even at this low dose, somatomedin
C levels increased 3-4 fold. It is disingenuous to state that
what was called an excellent response 25 years ago and
can still be considered as such, both in terms of growth
acceleration and IGF-1 generation, was a “limited response.”
To suggest that this experience played a role in advancing the
notion of a continuum of IGF-1 deﬁciency related to varying
GH responsiveness is contradicted by the data, and, quite
appropriately, was not suggested in the original paper.
It is diﬃcult to see how the discussion of variable eﬀects
ofvariousmutationsandpolymorphismsoftheGHreceptor
argues for “prime time” readiness of rhIGF-1 treatment for
other than the approved orphan indications. The closing
sentenceoftheparagraphstates,“In82subjectswhohadGH
insensitivity syndrome, 16 gene defects were found among
27 subjects; there was no relationship between the site or
type of mutation and neither height SDS or biochemical
parameters.” These were all subjects with Laron syndrome
due to GH resistance. There are no genetic data to support
the hypothesis of GH insensitivity in the 500 patients
recruited by pediatric endocrinologists to the rhIGF-1 trial.
The discussion of experience with rhIGF-1 in Laron
syndrome is noteworthy for failing to address the inferior
results in comparison to rhGH-treated GH deﬁciency [17].
The long-term study, on which FDA approval was
based,isreferencedundertheheading“Recombinanthuman
insulin-like growth factor-1 treatment of severe primary
insulin-like growth factor I deﬁciency.” This rubric assumes
that the subjects in the study with GH gene deletion who
developed GH neutralizing antibodies to rhGH (12% of the
group)have“severeprimaryIGFD.”However,thisetiologyis
not listed in the authors’ Box 1 “Molecular defects resulting
in primary insulin-like growth factor-1 deﬁciency or insulin-
like growth factor-1 resistance (conﬁrmed by molecular
analysis)” because they obviously do not have “primary
IGFD.” The authors of the referenced report avoided taxo-
nomiccontortionsbyaccuratelyreferringtotheirpopulation
categorically as having “severe IGF-1 deﬁciency” which was
diagnostically “due to GH insensitivity” [18].
It is stated that studies of children with less severe forms
of “primary IGFD” have been going on since 2000, but none
are referenced. Instead, a 2007 study of rhGH-treated GHD
and what is now being called “primary IGFD” is said to
have indicated that the group with “primary IGFD” had less
growth despite higher rhGH dosing [19]. However, in the
study cited there was no separate “primary IGFD” group, as
all of the subjects had low IGF-1 levels. There were 3 study
groups, one receiving titrated rhGH doses to achieve an IGF-
1S D So f−0.5 to +0.5, another to achieve an IGF-1 SDS
of +1.5 to +2.5, and the 3rd group to receive a standard
rhGH dose. The ﬁrst and last groups had nearly identical
change in height SDS from baseline over 2 years while the
high dose group, not surprisingly, had approximately 50%
greater increase. A majority of these patients (62%) had
normal GH responses to stimulation testing, which may be
an underestimate if a substantial number had CDGM and
were not primed with a sex steroid for their testing [12]. The
responsestorhGHinthisstudyshowedthatalowIGF-1with
normal GH is not associated with GH insensitivity.
Further support for the view that the “primary IGFD”
clinical study subjects did not have GH insensitivity comes
from the results of the IGF-1 generation test. The study
recruitshadgreaterIGF-1andIGFBP3responsestoGHthan
did normals, when the results are expressed as percentage
response. These patients had a 76.5% increase in mean IGF-
1 level and 34% increase in mean IGFBP3 concentration
in response to 5 days of rhGH administration [20]. Both
of these responses are approximately 50% greater than in
normals and conﬁrm GH sensitivity.
Discussion of the two rhIGF-1 clinical trials provides
further evidence for the null hypothesis regarding “primary
IGFD.” The mean growth velocity of the control group, as
is typical of CDGM and familial short stature, was normal,
which indicates normal GH-IGF-1 activity. Therapy with
twice daily rhIGF-1 signiﬁcantly increased height SDS, as
would also be expected with rhGH treatment, for which
there was not an arm. Noteworthy is that some subjects
had even better ﬁrst-year height velocities with once daily
dosing, which has been explained appropriately as lack
of suppression of GH for half of the day, another strong
indication of normal GH sensitivity [21].
Review of the safety of rhIGF-1 treatment begins with
a statement that, “Naturally occurring substances such as
insulin, GH, and IGF-1 that are developed as medications
using recombinant DNA technologies have an advantage
over other types of medication, because they are integral
components of normal physiologic processes. Thus, they
have clear mechanisms of action, and the consequences of
their deﬁciency or excess are deﬁned well.” It is diﬃcult
to imagine why these peptides would be considered more
eﬃcacious or safer and their eﬀects more clearly deﬁned
than manufactured hormones, such as cortisol, thyroid,
testosterone,orestrogen,whicharealsointegralcomponents
of normal physiologic processes and no more or less likely to
cause trouble when provided in pharmacologic rather than
physiologic doses.
For a product to be ready for “prime time,” safety and
eﬃcacy must be reasonably assured. When the condition
to be treated does not threaten health or life, safety is the
paramount consideration. Two abstracts are cited by Bright
et al. to suggest that “primary IGFD” patients have fewer
adverse events than has been documented in longer-term
treatment of GH insensitivity [22, 23]. Neither of these
abstracts is retrievable. There is no explanation why children
w i t hI S Sm i g h tb el e s sl i k e l yt od e v e l o pa d v e r s ee v e n t sf r o m
rhIGF-1 than patients with true GH resistance.
Considerable information is available from rhIGF-1
treatment for the approved indications, which fails to
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for rhIGF-1 is lower for children with “primary IGFD”
than for those with true GH insensitivity, or that the
frequency is consistent with that for rhGH treatment.
Adverse events for patients with GH insensitivity treated
with rhIGF-1 are cumulative, making it inappropriate to
compare short-term studies to these longer-term studies
without correcting for patient years. For example, over
10% of subjects will require tonsillectomy/adenoidectomy
as a result of the lymphoid hyperplasia that develops in
25% of patients and is associated with hypoacusis and
snoring, which will increase from 4% in the 1st year to
65% after several years of treatment [18]. Tympanostomy
tubes will be required in 16%. Nephrolithiasis has developed
in 3% of patients. Acromegaloid coarsening of the facial
features with disproportionate growth of the jaw is common,
particularly in adolescent subjects. Disproportionate fat
mass increase is typical and severe obesity has occasionally
occurred. Parotid swelling and facial nerve palsy have been
described. None oftheseareadverseeﬀectsoftreatmentwith
rhGH.
Benign intracranial hypertension (BIH) has been seen
in 4% of patients with GH receptor deﬁciency or GH inac-
tivating antibodies treated with rhIGF-1, for an estimated
90/10,000 patient years [18]; recent data from the Tercica
clinical trial provide a similar rate of 140/10,000 patient
years for those receiving therapeutic doses [24] .T h er a t ef o r
BIH in rhGH-treated GHD in the NCGS is comparatively
small, 15/10,000 patient years [25]. The diﬀerence in rates of
BIH with rhIGF-1 from rhGH-treated ISS may be the more
appropriate comparison. Among over 5000 rhGH-treated
subjects with ISS in the Pﬁzer International Growth Study
database and 4500 in the NCGS, there were no instances
of BIH in a combined 25,000 patient years of treatment
[25, 26]. For headache, there is a >100 fold diﬀerence,
28/10,000 patient years (rhGH) versus 3460/10,000 patient
years (rhIGF-1) in the long-term study of severe GH
insensitivity and a remarkably similar 3000/10,000 patient
years from the recent clinical trial in “primary IGFD” [18,
24, 26]. There were 10 arthralgia or myalgia events per
10,000 rhGH treatment years; the frequency with rhIGF-1
treatment of GH insensitivity is over 600/10,000 treatment
years [18, 27].
There is also recent concern about potentially life-
threatening allergic reactions, with reports of anaphylaxis
and generalized urticaria [28, 29]. Considering the relatively
small number of children who have been treated, two
reports of serious allergic reactions associated with rhIGF-1
treatment indicate the need to add major and minor allergic
reactions to the list of adverse events associated with rhIGF-1
treatment.
In the section on dose selection, it is stated that the goal
was to increase serum IGF-1 concentrations to the upper end
of the normal range for age, that is, +2SDS. This is a conﬁr-
mation of the need to attain pharmacologic concentrations,
ratherthanthephysiologic(replacement)levelswhichwould
be the case with genuine hormonal deﬁciency states, such as
hypothyroidism and adrenal insuﬃciency.
After declaring that dose selection was based on the goal
of attaining circulating IGF-1 levels of +2SDS, the statement
is made that outcomes are not linked to serum IGF-1
levels during treatment with rhIGF-1. These 2 statements
appear dissonant. In fact, the 2-year treatment study of
Ecuadorian subjects with GH receptor deﬁciency showed
signiﬁcant association between IGF-1 levels attained and
growth response. For the 1st year of treatment, change in
height age correlated with trough levels of IGF-1 with a P
value of 0.009, and in the 2nd year of 0.005 [17].
The authors state that it has become increasingly clear
that the major molecular defects described thus far to
explain “primary IGFD” represent only one end of the IGFD
spectrumandrepeattheunsupportable19%and25%ﬁgures
discussed earlier. They go on to claim that the European and
US approvals of rhIGF-1 for severe primary IGFD support
the concept of milder “primary IGFD,” which is a huge
speculative leap. Having made that leap, the authors indicate
that it is apparent that a sizable subset of ISS should no
longer be classiﬁed as such, but as “primary IGFD” and by
this reasoning whether rhIGF-1 should be optimal therapy.
As noted above, evidence for GH insensitivity in this group
remains to be found.
The compilation of evidence to challenge the assumption
of “primary IGFD” as part of the spectrum of GH resistance
explaining a substantial portion of ISS is completed when
the authors present an argument for combination rhGH and
rhIGF-1 therapy which, by deﬁnition, requires normal GH
sensitivity to be eﬀective.
In the discussion of combination therapy, reference is
once again made to the study of a group of children with
low IGF-1 levels of whom ∼2/3 had normal GH responses
as if they had been studied in 2 groups, GH deﬁciency and
primary IGFD, but they were not [19]. They emphasize the
need for achieving high concentrations of IGF-1 with rhGH
fortherapeuticeﬀect;thisrequirementwouldbeinconsistent
with GH insensitivity or “primary IGFD.” Rather, these
observations reﬂect the absence of a hormonal etiology,
requiring pharmacologic rather than physiologic levels of
IGF-1 for growth promotion. There is also an absence
of consideration that GH administration does not simply
increase endocrine IGF-1 concentration. There is, however,
appreciation of the fact that rhIGF-1 monotherapy causes
suppressionofnocturnal GH secretion. This recognition and
the suggestion that combination therapy might outperform
either rhGH or rhIGF-1 monotherapies counters the argu-
ment that GH insensitivity is the core problem for which
rhIGF-1 is indicated.
The basis for the promotion of rhIGF-1 reﬂected in the
paper of Bright et al. has been noted in the interesting and
informative book Normal at Any Cost [30]:
“In a replay of Genentech’s strategy with growth hormone
decades earlier, Tercica received orphan drug status based
on the rarity of the disorder, then immediately set out to
expandthemarket....AsTercica’spresidentandCEOcelebrated
[FDA] approval, he described to the business press how sales
reps and managers would be dispatched to talk to pediatric
endocrinologists “who form the basis of this short stature
market.... building a franchise in short stature and associated
metabolic disease.” Again, echoes of the recombinant growth
hormonestory....Tercicaestimatedsome60,000childrenevenlyInternational Journal of Pediatric Endocrinology 5
split between the United States and Western Europe have short
stature with some lesser degree of growth hormone insensi-
tivity, representing a $1 billion annual market opportunity.
The company would conduct continuing medical education
programs, medical symposia, and regional speaker programs
“aimed at establishing awareness of Increlex in the physician
community”.”
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